Cardiac monitoring for cardiologists
This article was originally published in The Gray Sheet
Executive Summary
Medtronic will market its CardioSight data access tool to cardiologists treating heart failure patients who have one of several of the firm's resynchronization therapy defibrillators or ICD models, including the InSync Sentry CRT-D with OptiVol fluid monitoring system. Medtronic notes that CardioSight can detect dangerous fluid levels in the thoracic cavity up to two weeks prior to symptom development. The monitoring device enables non-implanting physicians to download 90 days of the patient's cardiac rhythm trends to improve treatment efficiency. Medtronic's CareLink network enables implanting physicians to remotely monitor patients with an ICD or pacemaker...
You may also be interested in...
Cardiac patient management at Guidant
FDA approval of the Contak Renewal 3 RF cardiac resynchronization therapy defibrillator and Zoom Latitude programmer will allow physicians to use remote monitoring to evaluate patients at three times the interrogation speed of the firm's previous programmer. Guidant plans to introduce the technology in the U.S. in Q4. Medtronic markets the CardioSight data access tool to cardiologists whose patients have been implanted with a defibrillator such as the InSync Sentry (1"The Gray Sheet" Aug. 22, 2005, In Brief)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.